HIV vaccine - United Biomedical

Drug Profile

HIV vaccine - United Biomedical

Alternative Names: HIV synthetic peptide vaccine - United Biomedical; p2249f

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United Biomedical
  • Developer Nonindustrial source; United Biomedical
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 23 Sep 2016 Preclinical development is ongoing in USA (United Biomedical pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral, Injection)
  • 19 Jul 2001 A phase I trial of the V3 peptide vaccine has been added to the adverse events and Viral Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top